Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics
Open Access
- 17 March 2026
- journal article
- research article
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (3) , 102648
Abstract
No abstract availableKeywords
Funding Information
- Biogen
This publication has 34 references indexed in Scilit:
- Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral SclerosisAnnals of Neurology, 2025
- Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral SclerosisMuscle & Nerve, 2025
- Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegenerationJournal of Neural Transmission, 2021
- Opportunities and challenges for antisense oligonucleotide therapiesJournal of Inherited Metabolic Disease, 2020
- Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosisActa Neuropathologica, 2019
- GPNMB ameliorates mutant TDP‐43‐induced motor neuron cell deathJournal of Neuroscience Research, 2016
- Multiplexed Quantitative Proteomics for High-Throughput Comprehensive Proteome Comparisons of Human Cell Lines2015
- Current hypotheses for the underlying biology of amyotrophic lateral sclerosisAnnals of Neurology, 2009
- Inclusions of amyotrophic lateral sclerosis–linked superoxide dismutase in ventral horns, liver, and kidneyAnnals of Neurology, 2008
- Direct database searching with MALDI‐PSD spectra of peptidesRapid Communications in Mass Spectrometry, 1995